IDH2 and glioblastoma: The frequency of TP53 mutations in IDH-mutant (‘secondary’) glioblastomas is comparable to that in lower grade IDH-mutant astrocytomas from which these glioblastomas are derived via malignant progression, suggesting that TP53 aberrations are early lesions in these tumors [162].